Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer

NCT00320541 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00320541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00320541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
August 31, 2012
Enrollment
187 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer